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Abstract. We review the key topics of one of the areas with the biggest impact of 
the last years in the chemical and pharmaceutical industry that is Crystal 
Engineering. The relevance of polymorphs and co-crystals from different points of 
view is been highlighted and broadly illustrated by means of several recent 
examples of studies carried out in this field. In addition, the most suitable 
instrumental techniques and the intellectual property implications are reviewed. 
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1.  Introduction  
Crystal engineering is the rational design of functional molecular solids from neutral or ionic 
building blocks, using intermolecular interactions in the design strategy [1]. This field has its 
origins in organic chemistry and in physical chemistry. The expansion of crystal engineering during 
the last years as a research field has gone parallel with a significant interest in the origin and nature 
of intermolecular interactions and their use in the design and preparation of new crystalline 
structures.  
Active pharmaceutical ingredients (APIs) represent a particularly great challenge to crystal 
engineers because of both fundamental and applied reasons. APIs are inherently predisposed for 
self-assembly since their utility is normally the result of the presence of one or more 
supramolecular synthons. The crystalline materials obtain their fundamental physical properties 
from the molecular arrangement within the solid, and altering the placement and/or interactions 
between these molecules can have a direct impact on the properties of a particular solid. Usually, 
solid-state scientists call upon a variety of different strategies when trying to modify the chemical 
and physical solid-state properties of APIs, namely, the formation of polymorphs, hydrates, 
solvates, salts and co-crystals [2] (Fig. 1). 
 
 
Figure 1. Different solid forms of an API: polymorphs, 
solvates/hydrates, salts and co-crystals. 
Polymorphism is the ability of a substance to crystallize in different crystal modifications, each 
of them having the same chemical structure but different arrangements or conformations of the 
molecules in the crystal lattice. Polymorphs can differ in their chemical, physical and biological 
properties. There are many cases where insufficient exploration of possible crystallization and 
interconversion conditions caused serious delays in market launch and losses of revenue. Hence, 
the understanding and control of polymorphism and polymorphic behaviour is of considerable 
fundamental and practical importance. Moreover, a metastable polymorph is sometimes accepted 
for example to provide better handling/processing properties [3]. 
Crystallizing the API as a multicomponent crystal has been another accepted approach to 
generating form and physical property diversity. Hydrate and salt formation are the most common 
applications of this concept. Pharmaceutical hydrates are important due to the presence of water 
molecules in so many pharmaceutical drugs. On the other hand, it is estimated that over half of the 
medicines on the market are administered as salts. However, a major limitation within this 
approach is that the API must possess a suitable (basic or acidic) ionisable site. In comparison, the 
emerging field of pharmaceutical co-crystals (multicomponent assemblies held together by freely 
reversible, noncovalent interactions) offer a different pathway, where any API regardless of acidic, 
basic or ionisable groups, could potentially be co-crystallized [4]. 
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2.  Methodology and Applications  
2.1.  Relevance of polymorphs and co-crystals in the pharmaceutical and agrochemical industry 
Crystal polymorphism is a common phenomenon in the pharmaceutical industry because the solid-
state form is a significant quality attribute of a crystalline drug compound. The control of the 
desired crystal form during the manufacturing, storage or transport of a pharmaceutical substance is 
a key issue and losing this control can have serious economical effects due to the infringement of 
the intellectual property [5]. 
In addition, intrinsic properties of a drug substance candidate like its solubility or its chemical 
stability can be affected by its solid state. Poor physical properties of drug substances may be 
improved by using different crystal forms. Pharmaceutical formulations are developed in order to 
affect and improve solid-state properties of the drug substance in the final product [6]. 
Although polymorphism is a less frequent issue in agrochemicals, some important compounds, 
including pesticides and herbicides such as metazachlor exist in different polymorphic 
modifications [7] and their different solubility can affect the efficiency and toxicity of the pesticide. 
Finally, co-crystals of APIs represent a class of multi-component crystalline forms that are of 
interest for their advantageous physical properties and for intellectual property implications [8]. In 
the last years, a great number of patents have been issued involving new co-crystals of APIs 
together with pesticides, herbicides and fungicides. 
 
2.2. Polymorphs and co-crystals screening 
During the last decades, high-throughput methodologies have been developed to look for new 
polymorphs and co-crystals of relevant drug compounds. Initially, the design of screening methods 
was based on solution growth. However, other methods such as solvent-drop grinding, slurring and 
the use of experimentally-determined phase diagrams have been developed in order to screen as 
much as possible the polymorphic landscape of a target compound. Due to the fact that all these 
screening methods are very time consuming and expensive, modern computational virtual 
screening methodologies for co-crystals have appeared recently with very promising results [9]. 
 
2.3. Analytical Techniques 
Polymorphs and co-crystals represent different crystal structures of a compound. In principle, any 
physical or chemical property can a priori vary along the crystalline landscape of a compound and 
thus, practically any analytical technique able to measure properties of a crystalline material is 
suitable to study the solid state behaviour of a given compound. In this sense, the most useful 
techniques are: 
2.3.1. Differential Scanning Calorimetry (DSC). This technique measures the difference in the 
amount of heat required to increase the temperature of a sample and a reference as a function of 
temperature. Pure crystalline forms are characterized by their melting process and the polymorphic 
behaviour can be studied through the observed onset and enthalpy of any thermal phenomenon 
which can be accurately measured. Endotherms represent phenomena such as desolvation, phase 
transitions and melting. On the other side, exotherms are associated with crystallization, phase 
transitions and decomposition reactions. 
2.3.2. Thermogravimetry (TGA). Thermogravimetric analysis records the mass changes of a sample 
as a function of time and temperature under a controlled atmosphere. Although this technique does 
not give direct information about the existence of polymorphism, since all polymorphs have the 
same mass, it is crucial in determining the existence of solvates and the determination of their 
stoichiometries. During polymorph screening of drugs, TGA helps to confirm or discard the 
appearance of a new polymorph. 
2.3.3. X-ray Diffraction (XRD). This technique is probably the most useful in the detection of a new 
polymorph, co-crystal and solvate. There exist two 
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depending on the sample: powder diffra
diffraction when a single crystal can be isolated. Usually powder methods are used to characterize 
qualitatively a new crystal phase while the single crystal method is used to determine the crystal
structure. However, recently powder methods are being applied
microcrystalline solids. 
2.3.4. Thermomicroscopy. Hot stage microscopy 
with a digital camera which provides useful information about thermal events, including melting
solid-solid transitions, crystallization
the visual observation of a polymorphic transition or 
can provide very useful qualitative information about the polymorphic system under study. In 
addition, the observation of changes in size, shape, colour, etc
useful to detect the existence of polymorp
2.3.5. Other Techniques. Spectroscopic techniques such as 
Magnetic Resonance (NMR) 
of the same organic compound 
mixture of two forms. 
 
Figure 2: Differential Scanning Calorimeter
2.4. Crystal Engineering and intellectual property
Polymorphs and co-crystals of a drug can 
crystal forms of the same compound
pharmaceutical industry is extreme because the discovery of a new polymorph can be translated 
into the filing of a new patent application
new polymorph (or a co-crystal) with improved properties such as stability or solubility
marketed and displace other commercial polymorphs of the same API. 
years, such as the Zantac or Cefadroxil cases (involving huge amounts of money) highlight the 
importance of having a deep knowledge of the polymorphic landscape during the development of a 
new drug. This is particularly relevant sin
3.  Examples of applications
In this section, we show some 
key topics of crystal engineering in 
3.1.  Norfloxacin 
This API is a synthetic broad antibacterial 
gonorrhea, prostate and urinary tract infections
3 
ction for those polycrystalline samples and single crystal 
 also to solve the crystal structure of 
consists of a hot stage and a microscope equipped 
s, sublimations, desolvations and co-crystallizations
a melting onset is subjecti
. during hot stage experiments can be 
hism in a rapid screening study. 
Infrared, Raman and solid
can also provide useful information about different crystalline forms 
and can be used to identify a pure crystal form and quantify a 
 
. Figure 3: Thermomicroscope.
 
be protected by patents since they represent different 
 with different properties. The relevance of this issue in the 
 with important economical consequences. In this sense, a 
Many examples in recent 
ce generics started to be commercialized.
 
case studies conducted in our facilities which briefly illustrate the 
reference to the pharmaceutical industry and new mat
fluoroquinolone compound used in the treatment of 
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3.1.1. Anhydrous forms of Norfloxacin. The polymorphism screening on Norfloxacin conducted in 
our laboratory revealed the existence of up to three different anhydrous forms [11]. These three 
forms were characterized by means of X-ray Powder Diffraction (XRPD) (Fig. 4) and DSC (Fig. 
5). 
  
Figure 4: XRPD of forms A, B and C of 
Norfloxacin 
Figure 5: DSC thermograms of forms A, B and 
C of Norfloxacin 
 
Form A is the higher melting form (219ºC) and form C melts at 207ºC. On the other hand, the 
DSC thermogram of form B shows the melting endothermic process of form B followed by an 
exothermic process (crystallization of the higher melting form A, the most stable at melting 
temperature) which happens simultaneously, being the net heat flow smaller than the expected for 
the melting of form B. Finally, melting of crystallized form A occurs. Occasionally, samples of 
pure polymorph B show endothermic solid-solid transition of form B to form A, followed by 
melting of remaining form B and subsequent melting of form A (Fig. 6). 
 
Figure 6: DSC of form B showing rare 
occasions when the sample underwent partly 
a solid-phase conversion at 196 ºC before 
melting 
Figure 7: DSC of form A mixed with small 
amounts of form B, recorded at the heating 
rates of 1-40 ºC/min 
 
When polymorph A is mixed with small amounts of polymorph B, an endothermic phenomenon 
is observed at 196 ºC in a DSC experiment at 10 ºC/min, followed by melting of form A. Heating 
rate influences the onset temperature of the first endotherm whereas the onset temperature of the 
melting of form A is not affected (Fig. 7), thus confirming that the first endotherm is a solid-solid 
transition.  
It is of practical interest to know the relative thermodynamic stability of all forms. The main 
questions to solve are whether two polymorphs are monotropically (one form is more stable than 
the other at any temperature) or enantiotropically (a transition temperature exists, below and above 
which the stability order is reversed) related, and for an enantiotropic system, where transition 
50 100 150 200 250 300
Temperature (ºC)
Form C
Form B
Form A
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temperature lies. According to the “heat of transition rule” of Burger and Ramberger [12], forms A 
and B are enantiotropically related. Based on physicochemical data, a semi-schematic 
energy/temperature diagram was constructed in order to display the thermodynamic relationship of 
the three polymorphs at different temperatures (Fig. 8). 
 
Figure 8. Semi-schematic 
energy/temperature  diagram of 
Norfloxacin. 
 
 
 
3.1.2. Hydrates of Norfloxacin. Pharmaceutical hydrates are important due to the presence of water 
molecules in so many pharmaceutical drugs, which affects to a variety of physical and chemical 
properties such as the stability, solubility and dissolution rate. Usually, hydrates are less soluble 
than their anhydrous forms because the interaction between the compound and the water molecules 
confers an extra thermodynamical stability [13]. Norfloxacin is an example which contradicts that 
general rule because the hydrated forms are more soluble than the anhydrous one. This implies that 
the hydration process plays an important role in influencing the bioavailability of Norfloxacin and 
it has made its hydrates an interesting object of study. 
 
Figure 9: Water molecules forming channels 
in the crystal structure of form II 
Figure 10: Cooling-heating DSC experiment, 
where the reversibility of the solid-solid 
transition of NF sesquihydrate can be observed 
 
During this study, two polymorphs of Norfloxacin sesquihydrate were discovered and their 
crystal structures solved, one of them at low temperature [14] (Fig. 9). Taking into account that 
there could be a possibility for a phase transition while cooling, we decided to perform a DSC 
experiment cooling from room temperature to -150ºC and heating from -150ºC to room 
temperature. As it can be seen in Figure 10, a reversible solid-solid transition was observed at -
57ºC while cooling and at -41ºC while heating. This experiment allows us to establish the relative 
thermodynamic stability between both forms, which is a matter of great relevance. According to the 
heat of transition rule forms I and II are enantiotropically related, being form I the most stable at 
room temperature and form II the most stable under approximately -40ºC. It was also possible to 
study the reversible phase transition of form I to form II by means of thermomicroscopy (Fig. 11). 
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Moreover, the variable temperature XRPD experiment demonstrates that form I of NF 
sesquihydrate undergoes a phase transformation into form II while cooling down (Fig. 12).  
 
 
Figure 11: Photomicrographs of NF 
Sesquihydrate in polarized light. 
Figure 12: Variable XRPD of NF 
sesquihydrate showing the phase transition 
from form I to form II 
3.2.  Ziprasidone 
Ziprasidone is a poorly soluble drug in water, a factor that unfavorably affects its bioavailability 
[15]. Ziprasidone, an antipsychotic agent useful for the treatment of psychotic disorders of the 
schizophrenic types [16], is marketed under the name GEODON as an oral capsule and as an 
injectable drug. GEODON capsules contain the monohydrate hydrochloride salt of ziprasidone, 
whereas GEODON for injection contains ziprasidone mesylate trihydrate. The need for improved 
water soluble forms of ziprasidone has been recognized during the last years. Salts are usually 
employed for increasing aqueous solubility [17]. 
It is commonly accepted that the formation of a stable salt requires a difference of at least three 
units between the pKa value of the ionisable group and that of the counterion [18]. So, we selected 
a range of acids according to this information. A microscale screening allowed us to discard some 
acids from the selected list before completion of the study because no salt was isolated from these 
acids. Next, a screening at a larger scale was developed with the remaining acids. The obtained 
salts were characterized by DSC, XRPD, IR and 1H-NMR. Additionally, the aqueous solubility of 
these salts was determined in order to compare the data obtained with the previously known 
solubilities of hydrochloride and mesylate salts [19]. Results are reported in table 1. 
 
Table 1 Aqueous solubilities of ZP salts by HPLC at 25ºC 
Salt Aqueous solubility (µg/mL)a 
Free base 0.3 
Hydrochloride 80 
Mesylate 1000 
Phosphate 28 
Citrate 30 
Fumarate 55 
Oxalate 236 
Isethionate 1121 
Malate 475 
aSolubility values indicate the weight in µg of Ziprasidone calculated as the free base, per mL of water.  
 
As it can be seen, isethionate salt is the one with the highest solubility. However, the appearance 
of coloured impurities during its isolation together with the poor recovery forced us to reject this 
salt. Then, our efforts were directed towards the malate salt as the selected target for further studies 
due to its good solubility. Moreover, malic acid is generally regarded as safe (GRAS) by the Food 
and Drug Administration (FDA) and has previously been used in FDA-approved marketed drugs. 
H
N
O
Cl
N
N
S N
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The malate salt of ZP was found to exist in three anhydrous crystalline forms. Each form was 
characterized by means of DSC, XRPD, IR and 1H-NMR spectroscopy. The aqueous solubilities of 
the ZP malates were also evaluated (table 2). Interestingly, forms B and C show an improved, 
highly solubility value of 989 and 1084 µg/mL respectively, if compared to malate form A. In 
addition, these solubility values are in the same range as that of mesylate. In this sense, malate salts 
of ZP are good candidates for further pharmaceutical development.  
 
Table 2 Aqueous solubilities of the malate salts of ZP by HPLC 
Salt Aqueous solubility (µg/mL)a 
Malate form A 475 
Malate form B 989 
Malate form C 1084 
aSolubility values indicate the weight in µg of ziprasidone calculated as the free base, per mL of water 
3.3.  Triphenylglycol 
(S)-triphenylglycol is a chiral auxiliary reagent which has found wide application in asymmetric 
aldol additions and ester enolate imine condensations. It has been used also in synthesis of natural 
products and biological active compounds. Furthermore it has applications as a chiral solvating 
agent in NMR spectroscopy [20]. In order to explore the possible polymorphic behaviour of 
triphenylglycol, we decided to study by thermal analysis the amorphous form obtained from 
quenching the melt, instead of performing classical crystallizations methods [21]. Interestingly, the 
heating of the amorphous form in a DSC experiment shows a collection of crystallization and 
melting phenomena demonstrating the complex polymorphic system (Fig. 13). From the glassy 
state (glass transition at 32 ºC) form D crystallizes first and melts (mp 72 ºC) with crystallization of 
other phases. With continuous heating, forms E (mp 110 ºC), F (mp 116 ºC), B (mp 119 ºC) and A 
(mp 127 ºC) melt successively. It has been found that a heating rate of 10 ºC/min must be applied 
in order to observe the maximum number of polymorphs in a DSC experiment. Lower heating rates 
lead to the crystallization of fewer forms whereas higher heating rates are not suitable due to a loss 
in the resolution. The cooling rate during quenching seems to have no influence on the result. 
 
Figure 13: DSC of a quenched from the melt 
sample. 
Figure 14: DSC of five successive 
heating/cooling cycles. 
Since we were not able to isolate forms D, E and F by conventional crystallization methods, we 
explored alternative approaches in view of the observed thermal behaviour by DSC. After some 
heating/cooling cycles (Fig. 14) starting from form A in a DSC (heating rate 10 ºC/min), form E 
grows at expenses of form B. Crystallization of the various polymorphic forms are time and 
temperature dependent, and a thermodynamic/kinetic competition in the crystallization of the 
different forms from the melt is observed. This can be explained by some kind of kinetical 
amplification process leading to the metaestable form E. After four cycles, the relative intensities of 
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all forms remain invariable. This suggests that form E is the first crystallizing form which 
transforms into the other three forms by crystallization from the melt during heating. 
 3.4. Dibenzylsquaramide 
Secondary squaramides are a family of synthetic compounds that exhibit interesting and useful 
properties as supramolecular synthons. Previous studies of secondary squaramides in solution 
demonstrate that these compounds can exist in several conformations due to the partially restricted 
rotation of the C-N bond (anti/anti and anti/syn conformers) [22]. We have studied the solid state 
behaviour of secondary squaramides in order to establish relations between the aforementioned 
properties and their possible polymorphism.  
In this example we have chosen dibenzylsquaramide (DBZSQ) as the model compound to 
explore its possible polymorphic behaviour [23]. In order to obtain as many crystal forms as 
possible a polymorphic screening was carried out. DBZSQ is only soluble in polar media such as 
dimethyl formamide (DMF) and dimethyl sulfoxide (DMSO). Therefore different combinations of 
those solvents with polar and non polar antisolvents were tested at several concentrations and 
temperatures, with variable cooling rates, in both thermodynamic and kinetic conditions, revealing 
a polymorphic system consisting of three polymorphs according to their different X-ray patterns. 
 
Figure 15: DSC of a quenched from the melt 
sample. 
Figure 16: DSC of five successive 
heating/cooling cycles. 
 
The DSC analysis of the three forms show the same sharp endothermic phenomenon at 311ºC 
but two of them also show a low intensity broad endothermic phenomenon at 257ºC (Fig. 15). 
Variable heating rates confirm that the first phenomenon is a solid-solid transition, with the second 
one being a melting process. This can be interpreted in the following manner: two forms (B and C) 
transform during the DSC analysis in the same polymorph (A) which melts at 311ºC.  
Curiously, the transition temperature is observed around the same value in all the cases. 
Although several polymorphs can present the same melting value (e.g. conformational 
polymorphism), to the best of our knowledge this is the first time that two forms share the same 
transition temperature. Therefore, a misleading interpretation of this system could be concluded if 
based only on the DSC analysis. 
According to the heat of transition rule [12] forms B and C are enantiotropically related to form 
A. This means that form A is a metastable form at room temperature. In addition, the reversibility 
of the solid transition could be observed in both cases by a heating-cooling DSC experiment (Fig. 
16). Both forms B and C return to form B after cooling (confirmed by XRPD). 
All the examples reviewed highlight the necessity of a multidisciplinary approach to solve a 
polymorphic problem or to design new crystal structures. Scientists from diverse areas such as 
physical-organic chemistry, supramolecular chemistry, physics or X-ray diffraction spectroscopy 
usually work together in ambitious research projects looking for new crystalline solids with 
improved properties. 
Crystal Engineering Studies 
 9 
ChT.1 
References 
[1] Desiraju G.R. 2007, Angew Chem Int Ed 46 8342-8356. 
[2] Shan N., Zaworotko M.J. 2008, Drug Discovery Today 13 440-446 
[3] Bernstein J. 2002 Polymorphism in Molecular Crystals, Oxford Science Publications, 
Oxford 
[4] Schultheiss N., Newman A. 2009, Crystal Growth & Design 9 2950-2967 
[5] Lee A.Y., Erdemir D, Myerson A.S. 2011  The Annual Review of Chemical and 
Biomolecular Engineering 
[6] Giron D., Mutz M., Garnier S. 2004 Journal of Thermal Analysis and Calorimetry 77, 709-
747 
[7] Griesser U. J., Weigand D., Rollinger J. M., Haddow M., Gstrein E. 2004 Journal of 
Thermal Analysis and Calorimetry, 77, 511–522 
[8] Lara-Ochoa F., Espinosa-Pérez G. 2007, Crystal Growth & Design 7 1213-1215 
[9] Musumeci D., Hunter C. A., Prohens R., Scuderi S., McCabe J. F. 2011 Chem. Sci., 2, 883-
890 
[10] Mazuel C. 1991, Analytical Profiles of Drug Substances 20 557 
[11] Barbas R., Prohens R., Puigjaner C. 2007, Journal of Thermal Analysis and Calorimetry 89 
687-692 
[12] This rule states that if an endothermal transition (for a solid-state conversion) is observed at 
some temperature, it may be assumed that there is a transition point below it; i.e., the two 
forms are related enantiotropically 
[13] Khankari R.K., Grant D.J.W. 1995, Thermochimica Acta 248 61-79 
[14] Puigjaner C., Barbas R., Portell A., Font-Bardia M., Alcobé X., Prohens R. 2010, Crystal 
Growth & Design 10 2948-2953 
[15] Turczyn E., Cieplucha A., Khan Z., Wloch T., Dyba R. 2007, PCT Int. Appl. WO  
2007126322 
[16] Caley C.F., Cooper C.K. 2002, Annals of Pharmacotherapy 36 839 
[17] Srivijaya R., Vishweshwar P., Sreekanth B.R., Vyas K. 2008 CrystEngComm 10 283 
[18] Bastin R.J., Bowker M.J., Slater B.J. 2000, Org. Process. Res. Dev. 4 427 
[19] Portell A., Barbas R., Font-Bardia M., Dalmases P., Prohens R., Puigjaner C. 2009, 
CrystEngComm 11 791-795 
[20] Ridder D., Wunderlich H., Braun M. 1998 Eur. J. Org. Chem. 1071; Braun M., Sacha H., 
Galle D., Baskaran S. 1996 Pure Appl. Chem. 68 561 
[21] Barbas R., Polito M., Prohens R., Puigjaner C. 2007, Chem.Commun. 3538-3540 
[22] Rotger M.C., Piña N., Frontera A., Martorell G., Ballester P., Deyà P.M., Costa A. 2004 J. 
Org. Chem. 69 2302-2308 
[23] Portell A., Barbas R., Braga D., Polito M., Puigjaner C., Prohens R. 2009 CrystEngComm 11 
52-54 
